|
| Andhra Pradesh ~ India ~ International ~ City ~ Entertainment ~ Business ~ Bullion ~ Forex ~ Sports ~ Technology ~ Health ~ Features |
| Lung Cancer ~ Lung Cancer ~ Breast Cancer ~ Heart attack ~ All Health Topics |
|
Home
/ Health News / 2008 / February 2008 / February 27, 2008 Drug for anemic cancer patients raises death risk by 10pct |
Novel breast imaging technology can locate hard-to-detect cancers
Eating eggs during pregnancy affects breast cancer outcomes in offspring
Radiation therapy delay may lead to increased breast cancer recurrence
Extract of the plant cats claw may harbour dengue cure
A plant from the Amazon region called the cats claw has been found to be effective in combating dengue. ANI
Yeast studies provide clue about controlling cholesterol levels
Johns Hopkins researchers say that they have gained significant insights into the mechanism whereby a single-celled fungus regulates its version of cholesterol. ANI
Stress-related disorders deteriorates brains memory processing ability
Using functional MRI (fMRI), a researcher team, which was led by an Indian-origin scientist, has found that patients suffering from stress-related psychiatric disorders have impaired wiring in the area of the brain behind suppressing memory. ANI
Researchers at Northwestern Universitys Feinberg School of Medicine have found that drugs taken by millions of anaemic cancer patients to boost their red blood cells and health can in fact raise their risk of death.
Washington, Feb 27 : Researchers at Northwestern University's Feinberg School of Medicine have found that drugs taken by millions of anaemic cancer patients to boost their red blood cells and health can in fact raise their risk of death.
The FDA approved drugs, called to boost their red blood cells and health, can do so by possibly stimulating the growth of cancer cells. The finding came to light after a meta-analysis of 51 trials involving a total of 13,613 patients.
The research team found that cancer patients who took ESAs had a 10 percent increased risk of death as compared to those patients who kept away from the drugs.
"The FDA says if you use the drug in moderation, it should be safe. But our findings, in conjunction with basic science studies, raise the concern that the drug may be stimulating cancer and shortening cancer patients' survival," said Charles Bennett, M.D., the lead author of the study."It's troubling that 15 years after the drug came out, we finally came to this realization.
"The current FDA recommendation is these drugs are safe for cancer patients as long their hemoglobin levels aren't raised too high. Our data do not support that," he added.
r Stephen Lai, one of the study's co-authors who tested the response of cancer cells to an ESA called erythropoietin in the laboratory, said that the tests had shown that the dugs had a significant effect.
"We saw a dramatic change. Adding 'epo' (erythropoietin) to the cells increased their ability to migrate or invade. Our basic science findings and the clinical trial results suggest that giving cancer patients 'epo' for their anemia may actually cause their tumors to progress," he said.
The study also confirmed a previously known 57 percent increased risk of blood clots in the legs or lungs for cancer patients receiving ESAs.
Lai cautioned that various solid tumors such as breast cancer, colon cancer and melanoma may react differently to ESAs.
"The exact effect and size of that effect may be different depending upon the type of tumor. Additional research is clearly necessary, and we have to be careful about generalizing these results before further research is conducted," he said.
The study and its findings will be published in the Journal of the American Medical Association Wednesday, February 27.
ANI
